相关实验视频

Updated: May 9, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

在体外发现强大的CRBN招募表皮生长因子受体 (EGFR) 降解剂

Wenbo Hu¹, Jinmei He¹, Tianyu Xie¹

¹School of Pharmaceutical Sciences, Liaoning University, Shenyang, 110036, China.

Investigational new drugs

|April 29, 2025

概括

针对表皮生长因子受体 (EGFR) 的新型蛋白质分解向嵌合体 (PROTACs) 显示出治疗非小细胞肺癌 (NSCLC) 的前景. 这些新型化合物有效降解EGFR,可能克服对现有疗法的耐药性.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药用化学医学化学

背景情况:

皮表皮生长因子受体 (EGFR) 是非小细胞肺癌 (NSCLC) 的关键驱动因素,由氨酸激酶抑制剂 (TKI) 准.
对EGFRTKI的获得性耐药性是一个重大的临床挑战,需要新的治疗策略.
向蛋白解酶的仿真体 (PROTACs) 通过诱导向蛋白质降解,提供了一种新的方法.

研究的目的:

设计和合成针对EGFR的新型小分子PROTACs.
评估这些PROTACs在NSCLC细胞系中的抗增殖活性.
研究PROTACs在克服EGFR抑制剂耐药性的潜力.

主要方法:

使用WZ4002作为弹头的EGFR向PROTAC的设计和合成.
对A549和NCl-H1975NSCLC细胞系的抗增殖活性的评估.
使用免疫阻塞进行蛋白质表达分析,以确认目标参与.

主要成果:

几种合成的PROTACs对NCl-H1975细胞表现出中度至强度的抗增殖活性,特别是那些具有抗性突变的细胞.
化合物HJM-17和HJM-19被确定为对抗NCl-H1975细胞最有效的化合物.
HJM-17有效地降低了突变EGFR (EGFR^L858R/T790M) 的表达.

结论:

针对EGFR的新型PROTACs,如HJM-17和HJM-19,显示出NSCLC治疗的巨大潜力.
这些PROTAC可以有效地降解突变EGFR,提供克服TKI耐药性的策略.
开发的化合物为进一步研究基于PROTAC的NSCLC治疗提供了基础.

关键词:

防止扩散的效率防止扩散的效率降解降解是一种降解.欧洲农业基金会 (EGFR) 是一个.在NSCLCLC中,我们可以看到.这就是PROTAC.在WZ4002中使用.

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...